Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a note issued to investors on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.

Cellectis Stock Performance

Shares of CLLS stock opened at $2.51 on Friday. The company has a 50 day moving average price of $2.62 and a 200-day moving average price of $2.63. Cellectis has a 52 week low of $0.96 and a 52 week high of $3.77. The firm has a market capitalization of $139.26 million, a PE ratio of -1.50 and a beta of 3.12. The company has a quick ratio of 2.20, a current ratio of 2.20 and a debt-to-equity ratio of 0.57.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.